Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise's preclinical migraine programs.

Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory and sales milestones, could reach up to US $757 million plus royalties on future sales. As of the date of this announcement, Brise has already achieved several near-term milestones.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.